New drug FB102 begins first human safety tests

NCT ID NCT07623057

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This Phase 1 trial tests the safety and tolerability of a new drug called FB102 in 56 healthy volunteers. Participants receive either a single dose, multiple weekly doses, or a placebo. The study focuses on side effects and how the drug moves through the body, not on treating any disease.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

FB102

What could go wrong

This is a very early Phase 1 trial in healthy people, so it cannot show whether FB102 works for any disease. The main goal is safety, not treatment.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • University of Sunshine Coast, Morayfield

    Eastwood, Queensland, 4556, Australia

    Contact Phone: •••-•••-••••

    Contact